Abstract
Background: Psoriasis (Pso) is a common chronic inflammatory disease affecting the skin, both sexes, and all ages. It can be associated with other chronic inflammatory musculoskeletal disorders and certain drugs, including tumor necrosis factor α (TNFα) antagonists.
Case Presentation: A 64-year-old man with seronegative rheumatoid arthritis (RA) refractory to leflunomide and prednisone was treated with SB-4 (Benepali), an etanercept biosimilar 50mg/week subcutaneously. He responded well to the treatment, but a year later, he developed erythematous skin eruptions affecting mainly in the palms of both hands. Skin biopsy showed a picture compatible with Pso. SB-4 was discontinued, and the skin lesions disappeared with the addition of topical steroid therapy. This is the only case of psoriatic skin lesions associated with SB-4 treatment. Conclusion: Thus, we review and discuss the relevant literature of Pso cases related to SB-4 and other anti-TNFα biosimilars. Rheumatologists dealing with patients on anti-TNFα biosimilars should be aware of and recognize these complications.Keywords: RA, TNF inhibitors, autoimmune phenomena, psoriatic skin lesions, SB-4, TNFα.
Graphical Abstract
[1]
Rosman Z, Shoenfeld Y, Zandman-Goddard G. Biologic therapy for autoimmune diseases: an update. BMC Med 2013; 11: 88.
[http://dx.doi.org/10.1186/1741-7015-11-88] [PMID: 23557513]
[http://dx.doi.org/10.1186/1741-7015-11-88] [PMID: 23557513]
[2]
Pichler WJ. Adverse side-effects to biological agents. Allergy 2006; 61(8): 912-20.
[http://dx.doi.org/10.1111/j.1398-9995.2006.01058.x] [PMID: 16867042]
[http://dx.doi.org/10.1111/j.1398-9995.2006.01058.x] [PMID: 16867042]
[3]
Sfikakis PP, Kollias G. Tumor necrosis factor biology in experimental and clinical arthritis. Curr Opin Rheumatol 2003; 15(4): 380-6.
[http://dx.doi.org/10.1097/00002281-200307000-00003] [PMID: 12819464]
[http://dx.doi.org/10.1097/00002281-200307000-00003] [PMID: 12819464]
[4]
Lin J, Ziring D, Desai S, et al. TNFalpha blockade in human diseases: an overview of efficacy and safety. Clin Immunol 2008; 126(1): 13-30.
[http://dx.doi.org/10.1016/j.clim.2007.08.012] [PMID: 17916445]
[http://dx.doi.org/10.1016/j.clim.2007.08.012] [PMID: 17916445]
[5]
Voulgari PV, Alamanos Y, Nikas SN, Bougias DV, Temekonidis TI, Drosos AA. Infliximab therapy in established rheumatoid arthritis: an observational study. Am J Med 2005; 118(5): 515-20.
[http://dx.doi.org/10.1016/j.amjmed.2005.01.029] [PMID: 15866254]
[http://dx.doi.org/10.1016/j.amjmed.2005.01.029] [PMID: 15866254]
[6]
Markatseli TE, Alamanos Y, Saougou I, Voulgari PV, Drosos AA. Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study. Clin Exp Rheumatol 2012; 30(1): 31-8.
[PMID: 22153557]
[PMID: 22153557]
[7]
Papadopoulos CG, Gartzonikas IK, Pappa TK, et al. Eight-year survival study of first-line tumour necrosis factor α inhibitors in rheumatoid arthritis: real-world data from a university centre registry. Rheumatol Adv Pract 2019; 3(1): rkz007.
[http://dx.doi.org/10.1093/rap/rkz007] [PMID: 31431995]
[http://dx.doi.org/10.1093/rap/rkz007] [PMID: 31431995]
[8]
Saougou I, Markatseli TE, Papagoras C, Voulgari PV, Alamanos Y, Drosos AA. Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study. Semin Arthritis Rheum 2011; 40(5): 398-406.
[http://dx.doi.org/10.1016/j.semarthrit.2010.07.004] [PMID: 20843542]
[http://dx.doi.org/10.1016/j.semarthrit.2010.07.004] [PMID: 20843542]
[9]
Venetsanopoulou AI, Voulgari PV, Alamanos Y, Papadopoulos CG, Markatseli TE, Drosos AA. Persistent clinical response of infliximab treatment, over a 4-year period in ankylosing spondylitis. Rheumatol Int 2007; 27(10): 935-9.
[http://dx.doi.org/10.1007/s00296-007-0330-9] [PMID: 17357804]
[http://dx.doi.org/10.1007/s00296-007-0330-9] [PMID: 17357804]
[10]
Saougou I, Markatseli TE, Voulgari PV, Drosos AA. Maintained clinical response of infliximab treatment in ankylosing spondylitis: a 6-year long-term study. Joint Bone Spine 2010; 77(4): 325-9.
[http://dx.doi.org/10.1016/j.jbspin.2010.02.014] [PMID: 20452801]
[http://dx.doi.org/10.1016/j.jbspin.2010.02.014] [PMID: 20452801]
[11]
Markatseli TE, Papagoras C, Nikoli A, Voulgari PV, Drosos AA. Certolizumab for rheumatoid arthritis. Clin Exp Rheumatol 2014; 32(3): 415-23.
[PMID: 24447441]
[PMID: 24447441]
[12]
Pelechas E, Voulgari PV, Drosos AA. Golimumab for Rheumatoid Arthritis. J Clin Med 2019; 8(3): E387.
[http://dx.doi.org/10.3390/jcm8030387] [PMID: 30897745]
[http://dx.doi.org/10.3390/jcm8030387] [PMID: 30897745]
[13]
Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum 2005; 52(8): 2513-8.
[http://dx.doi.org/10.1002/art.21233] [PMID: 16052599]
[http://dx.doi.org/10.1002/art.21233] [PMID: 16052599]
[14]
Voulgari PV, Markatseli TE, Exarchou SA, Zioga A, Drosos AA. Granuloma annulare induced by anti-tumour necrosis factor therapy. Ann Rheum Dis 2008; 67(4): 567-70.
[http://dx.doi.org/10.1136/ard.2007.075663] [PMID: 17728330]
[http://dx.doi.org/10.1136/ard.2007.075663] [PMID: 17728330]
[15]
Exarchou SA, Voulgari PV, Markatseli TE, Zioga A, Drosos AA. Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors. Scand J Rheumatol 2009; 38(5): 328-31.
[http://dx.doi.org/10.1080/03009740902922612] [PMID: 19579151]
[http://dx.doi.org/10.1080/03009740902922612] [PMID: 19579151]
[16]
Pelechas E, Drosos AA. Etanercept biosimilar SB-4. Expert Opin Biol Ther 2019; 19(3): 173-9.
[http://dx.doi.org/10.1080/14712598.2019.1566456] [PMID: 30616405]
[http://dx.doi.org/10.1080/14712598.2019.1566456] [PMID: 30616405]
[17]
de Gannes GC, Ghoreishi M, Pope J, et al. Psoriasis and pustular dermatitis triggered by TNF-alpha inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007; 143(2): 223-31.
[http://dx.doi.org/10.1001/archderm.143.2.223] [PMID: 17310002]
[http://dx.doi.org/10.1001/archderm.143.2.223] [PMID: 17310002]
[18]
Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD. Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 2011; 31(11): 1409-17.
[http://dx.doi.org/10.1007/s00296-011-1999-3] [PMID: 21800117]
[http://dx.doi.org/10.1007/s00296-011-1999-3] [PMID: 21800117]
[19]
Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62(9): 2569-81.
[http://dx.doi.org/10.1002/art.27584] [PMID: 20872595]
[http://dx.doi.org/10.1002/art.27584] [PMID: 20872595]
[20]
Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30(2): 239-45.
[http://dx.doi.org/10.1038/clpt.1981.154] [PMID: 7249508]
[http://dx.doi.org/10.1038/clpt.1981.154] [PMID: 7249508]
[21]
Her M, Kavanaugh A. Alterations in immune function with biologic therapies for autoimmune disease. J Allergy Clin Immunol 2016; 137(1): 19-27.
[http://dx.doi.org/10.1016/j.jaci.2015.10.023] [PMID: 26768759]
[http://dx.doi.org/10.1016/j.jaci.2015.10.023] [PMID: 26768759]
[22]
Reilly E, Edwards C, Mackay K. Anti-TNF therapy induced arthritis in patients with inflammatory bowel disease. Oxford (Rheumatology) 2015; 54: i94.
[http://dx.doi.org/10.1093/rheumatology/kev088.111]
[http://dx.doi.org/10.1093/rheumatology/kev088.111]
[23]
Cobo-Ibáñez T, del Carmen Ordóñez M, Muñoz-Fernández S, Madero-Prado R, Martín-Mola E. Do TNF-blockers reduce or induce uveitis? Rheumatology (Oxford) 2008; 47(5): 731-2.
[http://dx.doi.org/10.1093/rheumatology/ken091] [PMID: 18346974]
[http://dx.doi.org/10.1093/rheumatology/ken091] [PMID: 18346974]
[24]
Korzenik J, Larsen MD, Nielsen J, Kjeldsen J, Nørgård BM. Increased risk of developing Crohn’s disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNFα agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease. Aliment Pharmacol Ther 2019; 50(3): 289-94.
[http://dx.doi.org/10.1111/apt.15370] [PMID: 31267570]
[http://dx.doi.org/10.1111/apt.15370] [PMID: 31267570]
[25]
Fiorino G, Danese S, Pariente B, Allez M. Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-α agents. Autoimmun Rev 2014; 13(1): 15-9.
[http://dx.doi.org/10.1016/j.autrev.2013.06.005] [PMID: 23777821]
[http://dx.doi.org/10.1016/j.autrev.2013.06.005] [PMID: 23777821]
[26]
Fréling E, Baumann C, Cuny JF, et al. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience. Am J Gastroenterol 2015; 110(8): 1186-96.
[http://dx.doi.org/10.1038/ajg.2015.205] [PMID: 26195181]
[http://dx.doi.org/10.1038/ajg.2015.205] [PMID: 26195181]
[27]
Nestle FO, Conrad C, Tun-Kyi A, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 2005; 202(1): 135-43.
[http://dx.doi.org/10.1084/jem.20050500] [PMID: 15998792]
[http://dx.doi.org/10.1084/jem.20050500] [PMID: 15998792]
[28]
Palucka AK, Blanck JP, Bennett L, Pascual V, Banchereau J. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci USA 2005; 102(9): 3372-7.
[http://dx.doi.org/10.1073/pnas.0408506102] [PMID: 15728381]
[http://dx.doi.org/10.1073/pnas.0408506102] [PMID: 15728381]
[29]
Seneschal J, Milpied B, Vergier B, Lepreux S, Schaeverbeke T, Taïeb A. Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments. Br J Dermatol 2009; 161(5): 1081-8.
[http://dx.doi.org/10.1111/j.1365-2133.2009.09329.x] [PMID: 19681863]
[http://dx.doi.org/10.1111/j.1365-2133.2009.09329.x] [PMID: 19681863]
Article Metrics
36
1